Add Yahoo as a preferred source to see more of our stories on Google. Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Phase 2b POLAR study, a global, randomized, double-blind, placebo-controlled clinical trial evaluating GLM101 for the ...

The trial has dosed 43 children and adults aged four to 47 years with PMM2-CDG.

Please provide your email address to receive an email when new articles are posted on . Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a ...

IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE ...

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and degenerative neuromuscular disorder, which is normally diagnosed during adolescence. Friedreich’s ataxia is caused by a ...

Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025, focusing on ...

A new study reports the identification of a previously unknown genetic cause of a late-onset cerebellar ataxia, a discovery that will improve diagnosis and open new treatment avenues for this ...

Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...